Geode Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,079,645
| Closed | -$2.46M | – | 4599 |
|
|
2024
Q2 | $2.46M | Buy |
1,079,645
+573,840
| +113% | +$2.19M | ﹤0.01% | 3064 |
|
|
2024
Q1 | $2.19M | Buy |
505,805
+45,030
| +10% | +$157K | ﹤0.01% | 3080 |
|
|
2023
Q4 | $1.41M | Buy |
460,775
+20,142
| +5% | +$37.8K | ﹤0.01% | 3215 |
|
|
2023
Q3 | $635K | Buy |
440,633
+8,981
| +2% | +$17.4K | ﹤0.01% | 3509 |
|
|
2023
Q2 | $1.07M | Sell |
431,652
-6,742
| -2% | -$18.4K | ﹤0.01% | 3323 |
|
|
2023
Q1 | $1.17M | Buy |
438,394
+83,855
| +24% | +$403K | ﹤0.01% | 3271 |
|
|
2022
Q4 | $1.93M | Buy |
354,539
+7,284
| +2% | +$61K | ﹤0.01% | 3060 |
|
|
2022
Q3 | $4.34M | Buy |
347,255
+5,360
| +2% | +$61.2K | ﹤0.01% | 2750 |
|
|
2022
Q2 | $1.69M | Sell |
341,895
-326,245
| -49% | -$1.81M | ﹤0.01% | 3175 |
|
|
2022
Q1 | $5.08M | Sell |
668,140
-47,233
| -7% | -$448K | ﹤0.01% | 2793 |
|
|
2021
Q4 | $7.3M | Buy |
715,373
+72,270
| +11% | +$921K | ﹤0.01% | 2659 |
|
|
2021
Q3 | $8.63M | Buy |
643,103
+32,779
| +5% | +$534K | ﹤0.01% | 2567 |
|
|
2021
Q2 | $13.4M | Buy |
610,324
+59,141
| +11% | +$1.31M | ﹤0.01% | 2258 |
|
|
2021
Q1 | $13.3M | Buy |
551,183
+67,343
| +14% | +$1.57M | ﹤0.01% | 2157 |
|
|
2020
Q4 | $8.7M | Buy |
483,840
+17,712
| +4% | +$265K | ﹤0.01% | 2266 |
|
|
2020
Q3 | $5.38M | Sell |
466,128
-1,793
| -0.4% | -$29.6K | ﹤0.01% | 2349 |
|
|
2020
Q2 | $11.4M | Buy |
467,921
+10,086
| +2% | +$167K | ﹤0.01% | 1862 |
|
|
2020
Q1 | $5.04M | Buy |
457,835
+42,130
| +10% | +$787K | ﹤0.01% | 2141 |
|
|
2019
Q4 | $11M | Buy |
415,705
+14,989
| +4% | +$351K | ﹤0.01% | 1946 |
|
|
2019
Q3 | $9.13M | Buy |
400,716
+20,116
| +5% | +$634K | ﹤0.01% | 2000 |
|
|
2019
Q2 | $11.7M | Buy |
380,600
+68,370
| +22% | +$1.44M | ﹤0.01% | 1839 |
|
|
2019
Q1 | $5.18M | Buy |
312,230
+33,167
| +12% | +$629K | ﹤0.01% | 2313 |
|
|
2018
Q4 | $5.34M | Buy |
279,063
+26,098
| +10% | +$977K | ﹤0.01% | 2181 |
|
|
2018
Q3 | $13.2M | Buy |
252,965
+33,554
| +15% | +$1.83M | ﹤0.01% | 1715 |
|
|
2018
Q2 | $9.54M | Buy |
219,411
+33,434
| +18% | +$1.43M | ﹤0.01% | 1903 |
|
|
2018
Q1 | $6.89M | Buy |
185,977
+91,611
| +97% | +$2.44M | ﹤0.01% | 2036 |
|
|
2017
Q4 | $1.87M | Buy |
94,366
+8,061
| +9% | +$173K | ﹤0.01% | 2787 |
|
|
2017
Q3 | $2.15M | Buy |
86,305
+76,085
| +744% | +$1.41M | ﹤0.01% | 2697 |
|
|
2017
Q2 | $178K | Buy |
+10,220
| New | +$179K | ﹤0.01% | 3729 |
|
Geode Capital Management's GTHX Position: Q3 2024 in Review
Geode Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 1,079,645 shares — an estimated $2.46M sold.
Geode Capital Management first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $13.4M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Geode Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Geode Capital Management sold 1,079,645 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $2.46M.
- Geode Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- Geode Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $13.4M in Q2 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.